Carmen Burtea1, Sophie Laurent1, Eric Lancelot2, Olivier Rousseaux2, Sbastien Ballet2, Coralie Thirifays1, Marc Port2, Grard Toubeau3, Luce Vander Elst1, Claire Corot2, Robert Nicolas Muller1
1General, Organic and Biomedical Chemistry, NMR and Molecular Imaging Laboratory, University of Mons, Mons, Belgium; 2Research Center, Guerbet, Aulnay-sous-Bois, France; 3Laboratory of Histology, University of Mons, Mons, Belgium
A VCAM-1-targeted cyclic heptapeptide peptide was conjugated to USPIO (USPIO-R832), and VCAM-1 binding was first confirmed on HUVEC stimulated with TNF-alpha. Subsequently, USPIO-R832 was evaluated by MRI at 4.7T on ApoE-KO mice, by using T2 and T2*-weighted imaging sequences. The ability to bind to atherosclerotic plaque of this molecular imaging probe was furthermore corroborated by histochemistry. The control imaging probe was represented by USPIO vectorized by a non-specific peptide (USPIO-NSP).